- Home
- INCY vs ACM Comparison
INCY vs ACM Comparison
Compare INCY & ACM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- ACM
- Stock Information
- Founded
- INCY 1991
- ACM 1980
- Country
- INCY United States
- ACM United States
- Employees
- INCY N/A
- ACM N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- ACM Military/Government/Technical
- Sector
- INCY Health Care
- ACM Consumer Discretionary
- Exchange
- INCY Nasdaq
- ACM Nasdaq
- Market Cap
- INCY 13.0B
- ACM 14.7B
- IPO Year
- INCY 1993
- ACM 2007
- Fundamental
- Price
- INCY $86.92
- ACM $119.56
- Analyst Decision
- INCY Buy
- ACM Strong Buy
- Analyst Count
- INCY 20
- ACM 10
- Target Price
- INCY $79.06
- ACM $128.50
- AVG Volume (30 Days)
- INCY 1.9M
- ACM 806.9K
- Earning Date
- INCY 07-29-2025
- ACM 08-04-2025
- Dividend Yield
- INCY N/A
- ACM 0.87%
- EPS Growth
- INCY 900.04
- ACM 147.22
- EPS
- INCY 4.37
- ACM 4.59
- Revenue
- INCY $4,584,996,000.00
- ACM $16,074,699,000.00
- Revenue This Year
- INCY $13.53
- ACM $3.29
- Revenue Next Year
- INCY $10.38
- ACM $5.98
- P/E Ratio
- INCY $19.90
- ACM $23.71
- Revenue Growth
- INCY 18.87
- ACM 1.50
- 52 Week Low
- INCY $53.56
- ACM $85.00
- 52 Week High
- INCY $87.06
- ACM $122.04
- Technical
- Relative Strength Index (RSI)
- INCY 80.83
- ACM 61.18
- Support Level
- INCY $76.45
- ACM $119.20
- Resistance Level
- INCY $79.43
- ACM $122.04
- Average True Range (ATR)
- INCY 2.57
- ACM 2.28
- MACD
- INCY 1.01
- ACM 0.47
- Stochastic Oscillator
- INCY 99.13
- ACM 81.25
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About ACM AECOM
Aecom is one of the largest global providers of design, engineering, construction, and management services. It serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $16.1 billion in sales in fiscal 2024.